Publications

 

ACETAZOLAMIDE VERSUS PLACEBO FOR CEREBRAL OEDEMA REQUIRING DEXAMETHASONE IN RECURRENT AND/OR PROGRESSIVE HIGH-GRADE GLIOMA: PHASE II RANDOMISED PLACEBO-CONTROLLED DOUBLE-BLIND STUDY
Agar MR, Nowak AK, Hovey EJ, Barnes EH, Simes J, Vardy JL, Wheeler HR, Kong BY, Leonard R, Hall M, Tim E, Spyridopoulos D, Sim HW, Lwin Z, Dowling A, Harrup R, Jennens R, Kichenadasse G, Dunlop T, Gzell C, Koh ES. Acetazolamide versus placebo for cerebral oedema requiring dexamethasone in recurrent and/or progressive high-grade glioma: phase II randomised placebo-controlled double-blind study. BMJ Support Palliat Care. 2023 Feb 17: spcare-2022-004119. doi: 10.1136/spcare-2022-004119. Epub ahead of print. PMID: 36807048.

 

DETERMINING THE RESEARCH PRIORITIES FOR ADULT PRIMARY BRAIN TUMOURS IN AUSTRALIA AND NEW ZEALAND: A DELPHI STUDY WITH CONSUMERS, HEALTH PROFESSIONALS, AND RESEARCHERS
Georgia K. B. Halkett, Lauren J. Breen, Melissa Berg, Rebecca Sampson, Hao-Wen Sim, Hui K. Gan, Benjamin Y. Kong, Anna K. Nowak, Bryan W. Day, Rosemary Harrup, Melissa James, Frank Saran, Brett Mcfarlane, Chris Tse, Eng-Siew Koh. Determining the Research Priorities for Adult Primary Brain Tumours in Australia and New Zealand: A Delphi Study with Consumers, Health Professionals, and Researchers. Current Oncology. Volume 29, Issue 12, December 2022; https://www.mdpi.com/1718-7729/29/12/781

 

NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA
Hao-Wen Sim, Zarnie Lwin, Elizabeth H. Barnes, Kerrie L. McDonald, Sonia Yip, Roel Verhaak, Amy B. Heimberger, Merryn Hall, Matthew Wong, Ross Jennens, David M. Ashley, Mark Rosenthal, Elizabeth Hovey, Benjamin Ellingson, Annette Tognela, Hui Gan, Michael Back, Eng- Siew Koh, Anne Long, Katharine Cuff, Stephen Begbie, Craig Gedye, Anna Mislang, Hien Le, Margaret O. Johnson, Benjamin Y. Kong, John Simes, Mustafa Khasraw. NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed elderly patients with glioblastoma. Society for NeuroOncology (SNO) conference, 17-20 November 2022, Tampa,Florida, USA. https://doi.org/10.1093/neuonc/noac209.256.

GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA
Hao-Wen Sim, Zarnie Lwin, Elizabeth H. Barnes, Kerrie L. McDonald, Eng-Siew Koh, Mark Rosenthal, Matthew C. Foote, Michael Back, Helen Wheeler, Michael E. Buckland, Kyle Walsh, Lauren Fisher, Robyn Leonard, Merryn Hall, David M. Ashley, Sonia Yip, John Simes, Erik P. Sulman, Mustafa Khasraw. Genome-wide DNA methylation patterns in VERTU: A randomized phase II trial of veliparib, radiotherapy and temozolomide in patients with MGMT-unmethylated glioblastoma. Society for NeuroOncology (SNO) conference, 17-20 November 2022, Tampa,Florida, USA. https://doi.org/10.1093/neuonc/noac209.307.

MULTI-ARM GLIOBLASTOMA AUSTRALASIA (MAGMA): PROTOCOL FOR A MULTI-ARM RANDOMISED CLINICAL TRIAL FOR PEOPLE AFFECTED BY GLIOBLASTOMA
Kong BY, Sim, H-W, Barnes EH, Nowak AK, Hovey EJ, Jeffree R, Harrup R, Parkinson J, Gan HK, Pinkham MB, Yip S, Hall M, Tu E, Carter C, Koh, E-S., Lwin Z, Dowling A, Simes JS, Gedye, C. Multi-Arm GlioblastoMa Australasia (MAGMA): Protocol for a multi-arm randomised clinical trial for people affected by glioblastoma. BMJ Open - Volume 12, Issue 9, 2022. Online issue publication September 14, 2022. https://bmjopen.bmj.com/content/12/9/e058107.

PATTERNS OF CARE IN ADULT HISTONE MUTANT GLIOMAS: RESULTS OF AN INTERNATIONAL SURVEY
Alexander Yuile, Mustafa Khasraw2, Justin T Low, Kyle M Walsh, Eric Lipp, Joanne Sy, Laveniya Satgunaseelan, Marina Ann Kastelan, Madhawa De Silva, Adrian Lee, Helen Wheeler. Patterns of care in adult histone mutant gliomas: results of an international survey. Neuro-Oncology Practice, 05 June 2022; npac047, https://doi.org/10.1093/nop/npac047

TEMOZOLOMIDE AND RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN PATIENTS WITH GLIOBLASTOMA, IDH-WILDTYPE: POST-HOC ANALYSIS OF THE EORTC RANDOMIZED PHASE 3 CATNON
C. Mircea S. Tesileanu, Marc Sanson, Wolfgang Wick, Alba A. Brandes, Paul M. Clement, Sara C. Erridge, Michael A. Vogelbaum, MD, Anna K. Nowak, Jean-Francois Baurain, Warren P. Mason, Helen Wheeler, Olivier L. Chinot, Sanjeev Gill, Matthew Griffin, Leland Rogers, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Myra E. van Linde, Kenneth Aldape, Robert B. Jenkins, Johan M. Kros, Pieter Wesseling, Andreas von Deimling, Youri Hoogstrate, Iris de Heer, Peggy N. Atmodimed, Hendrikus J. Dubbink, Rutger W.W. Brouwer, Wilfred F.J. van IJcken, Kin Jip Cheung, Vassilis Golfinopoulos, Brigitta G. Baumert, Thierry Gorlia, Pim J. French, Martin J. van den Bent. Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON. Clin Cancer Res. 2022 June 13; 28(12): 2527–2535. doi:10.1158/1078-0432.CCR-21-4283.

LUMOS - LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES AT RELAPSE: PROTOCOL FOR A PILOT STUDY
Benjamin Y Kong, Hao-Wen Sim, Anna K Nowak, Sonia Yip, Elizabeth H Barnes, Bryan W Day, Michael E Buckland, Roel Verhaak, Terrance Johns, Cleo Robinson, Marc A Thomas, Tindaro Giardina, Zarnie Lwin, Andrew M Scott, Jonathon Parkinson, Rosalind Jeffree, Richard de Abreu Lourenco, Elizabeth J Hovey, Lawrence M Cher, Ganessan Kichendasse, Mustafa Khasraw, Merryn Hall, Emily Tu, Benhur Amanuel, Eng-Siew Koh, Hui K Gan. LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study. BMJ Open. Published online 30 December 2021. Article available on http://dx.doi.org/10.1136/bmjopen-2021-054075

 

OUTCOMES FROM THE USE OF COMPUTERIZED NEUROCOGNITIVE TESTING IN A RECURRENT GLIOBLASTOMA CLINICAL TRIAL
K.M.Field, E.H.Barnes, H.W.Sim, A.K.Nowak, J.Simes, M.A.Rosenthal, H.Wheeler, E.J.Hovey, L.M.Cher. Outcomes from the use of computerized neurocognitive testing in a recurrent glioblastoma clinical trial. Journal of Clinical Neuroscience. Published online 12 November 2021. Article available on https://doi.org/10.1016/j.jocn.2021.10.022

 

DEVELOPMENT OF RANDOMIZED TRIALS IN ADULTS WITH MEDULLOBLASTOMA—THE EXAMPLE OF EORTC 1634-BTG/NOA-23
Peter Hau, Didier Frappaz, Elizabeth Hovey, Martin G. McCabe, Kristian W. Pajtler, Benedikt Wiestler, Clemens Seidel, Stephanie E. Combs, Linda Dirven, Martin Klein, Antoinette Anazodo, Elke Hattingen, Silvia Hofer, Stefan M. Pfister, Claus Zimmer, Rolf-Dieter Kortmann, Marie-Pierre Sunyach, Ronan Tanguy, Rachel Effeney, Andreas von Deimling, Felix Sahm, Stefan Rutkowski, Anna S. Berghoff, Enrico Franceschi, Estela Pineda, Dagmar Beier, Ellen Peeters, Thierry Gorlia, Maureen Vanlancker, Jacoline E. C. Bromberg, Julien Gautier, David S. Ziegler, Matthias Preusser, Wolfgang Wick and Michael Weller. Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23. Cancers. Published online 9 July 2021. Article available on https://doi.org/10.3390/cancers13143451
 

BARRIERS AND POTENTIAL SOLUTIONS TO INTERNATIONAL COLLABORATION IN NEURO-ONCOLOGY CLINICAL TRIALS: CHALLENGES FROM THE AUSTRALIAN PERSPECTIVE
Benjamin Y. Kong, Candace Carter, Anna K. Nowak, Elizabeth Hovey, Zarnie Lwin, Neda Haghighi, Hui K. Gan, Hao-Wen Sim, David S. Ziegler, Kirston Barton, Jonathon Parkinson, Robyn Leonard, Mustafa Khasraw, Matthew Foote. Barriers and potential solutions to international collaboration in neuro-oncology clinical trials: Challenges from the Australian perspective. Asia-Pacific Journal of Clinical Oncology. Published online 24 June 2021. Article available on https://doi.org/10.1111/ajco.13606

 

ADJUVANT AND CONCURRENT TEMOZOLOMIDE FOR 1P/19Q NON-CO-DELETED ANAPLASTIC GLIOMA (CATNON; EORTC STUDY 26053-22054): SECOND INTERIM ANALYSIS OF A RANDOMISED, OPEN-LABEL, PHASE 3 STUDY
Martin J van den Bent, C Mircea S Tesileanu, Wolfgang Wick, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Sarah Erridge, Michael A Vogelbaum, Anna K Nowak, Jean Français Baurain, Warren P Mason, Helen Wheeler, Olivier L Chinot, Sanjeev Gill, Matthew Griffin, Leland Rogers, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Jaap Reijneveld, Roelien H Enting, Francesca Caparrotti, Thierry Lesimple, Susan Clenton, Anja Gijtenbeek, Elizabeth Lim, Ulrich Herrlinger, Peter Hau, Frederic Dhermain, Iris de Heer, Kenneth Aldape, Robert B Jenkins, Hendrikus Jan Dubbink, Johan M Kros, Pieter Wesseling, Sarah Nuyens, Vassilis Golfinopoulos, Thierry Gorlia, Pim French, Brigitta G Baumert. Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. The Lancet. Published online 14 May 2021. Article available on https://doi.org/10.1016/S1470-2045(21)00090-5
 

A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY, AND TEMOZOLOMIDE IN PATIENTS WITH UNMETHYLATED MGMT GLIOBLASTOMA: THE VERTU STUDY
Hao-Wen Sim, Kerrie L McDonald, Zarnie Lwin, Elizabeth H Barnes, Mark Rosenthal, Matthew C Foote, Eng-Siew Koh, Michael Back, Helen Wheeler, Erik P Sulman, Michael E Buckland, Lauren Fisher, Robyn Leonard, Merryn Hall, David M Ashley, Sonia Yip, John Simes, Mustafa Khasraw. A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: the VERTU study. Neuro-Oncology. Published online 13 May 2021. Article available on https://doi.org/10.1093/neuonc/noab111
 

PROGNOSTIC SIGNIFICANCE OF GENOME-WIDE DNA METHYLATION PROFILES WITHIN THE RANDOMISED, PHASE 3, EORTC CATNON TRIAL ON NON-1P/19Q DELETED ANAPLASTIC GLIOMA
C M S Tesileanu, M J van den Bent, M Sanson, W Wick, A A Brandes, P M Clement, S C Erridge, M A Vogelbaum, A K Nowak, J F Baurain, W P Mason, H Wheeler, O L Chinot, S Gill, M Griffin, L Rogers, W Taal, R Rudà, M Weller, C McBain, M E van Linde, T S Sabedot, Y Hoogstrate, A von Deimling, I de Heer, W F J van IJcken, R W W Brouwer, K Aldape, R B Jenkins, H J Dubbink, J M Kros, P Wesseling, K J Cheung, V Golfinopoulos, B G Baumert, T Gorlia, H Noushmehr, P J French. Prognostic significance of genome-wide DNA methylation profiles within the randomised, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma. Neuro-Oncology. Published online 29 April 2021. Article available on https://doi.org/10.1093/neuonc/noab088

 

NON-IDH1-R132H IDH1/2 MUTATIONS ARE ASSOCIATED WITH INCREASED DNA METHYLATION AND IMPROVED SURVIVAL IN ASTROCYTOMAS, COMPARED TO IDH1-R132H MUTATIONS
C. Mircea S. Tesileanu, Wies R. Vallentgoed, Marc Sanson, Walter Taal, Paul M. Clement, Wolfgang Wick, Alba Ariela Brandes, Jean Francais Baurain, Olivier L. Chinot, Helen Wheeler, Sanjeev Gill, Matthew Griffin, Leland Rogers, Roberta Rudà, Michael Weller, Catherine McBain, Jaap Reijneveld, Roelien H. Enting, Francesca Caparrotti, Thierry Lesimple, Susan Clenton, Anja Gijtenbeek, Elizabeth Lim, Filip de Vos, Paul J. Mulholland, Martin J. B. Taphoorn, Iris de Heer, Youri Hoogstrate, Maurice de Wit, Lorenzo Boggiani, Sanne Venneker, Jan Oosting, Judith V. M. G. Bovée, Sara Erridge, Michael A. Vogelbaum, Anna K. Nowak, Warren P. Mason, Johan M. Kros, Pieter Wesseling, Ken Aldape, Robert B. Jenkins, Hendrikus J. Dubbink, Brigitta Baumert, Vassilis Golfinopoulos, Thierry Gorlia, Martin van den Bent & Pim J. French. Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations. Acta Neuropathologica. Published online 19 March 2021. Article available on https://doi.org/10.1007/s00401-021-02291-6
 

MANAGEMENT OF GLIOBLASTOMA: AN AUSTRALIAN PERSPECTIVE
Hao-Wen Sim, Anna K. Nowak, Zarnie Lwin, Mustafa Khasraw. Management of glioblastoma: an Australian perspective. Chinese Clinical Oncology.  Published online 3 Feb 2020. Article available on https://doi.org/10.21037/cco.2020.02.05.

LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS
Floris P. Barthel, Kevin C. Johnson, Frederick S. Varn, Anzhela D. Moskalik, Georgette Tanner, Emre Kocakavuk, Kevin J. Anderson, Olajide Abiola, Kenneth Aldape, Kristin D. Alfaro, Donat Alpar, Samirkumar B. Amin, David M. Ashley, Pratiti Bandopadhayay, Jill S. Barnholtz-Sloan, Rameen Beroukhim, Christoph Bock, Priscilla K. Brastianos, Daniel J. Brat, Andrew R. Brodbelt, Alexander F. Bruns, Ketan R. Bulsara, Aruna Chakrabarty, Arnab Chakravarti, Jeffrey H. Chuang, Elizabeth B. Claus, Elizabeth J. Cochran, Jennifer Connelly, Joseph F. Costello, Gaetano Finocchiaro, Michael N. Fletcher, Pim J. French, Hui K. Gan, Mark R. Gilbert, Peter V. Gould, Matthew R. Grimmer, Antonio Iavarone, Azzam Ismail, Michael D. Jenkinson, Mustafa Khasraw, Hoon Kim, Mathilde C. M. Kouwenhoven, Peter S. LaViolette, Meihong Li, Peter Lichter, Keith L. Ligon, Allison K. Lowman, Tathiane M. Malta, Tali Mazor, Kerrie L. McDonald, Annette M. Molinaro, Do-Hyun Nam, Naema Nayyar, Ho Keung Ng, Chew Yee Ngan, Simone P. Niclou, Johanna M. Niers, Houtan Noushmehr, Javad Noorbakhsh, D. Ryan Ormond, Chul-Kee Park, Laila M. Poisson, Raul Rabadan, Bernhard Radlwimmer, Ganesh Rao, Guido Reifenberger, Jason K. Sa, Michael Schuster, Brian L. Shaw, Susan C. Short, Peter A. Sillevis Smitt, Andrew E. Sloan, Marion Smits, Hiromichi Suzuki, Ghazaleh Tabatabai, Erwin G. Van Meir, Colin Watts, Michael Weller, Pieter Wesseling, Bart A. Westerman, Georg Widhalm, Adelheid Woehrer, W. K. Alfred Yung, Gelareh Zadeh, Jason T. Huse, John F. De Groot, Lucy F. Stead, Roel G. W. Verhaak* & The GLASS Consortium. Longitudinal molecular trajectories of diffuse glioma in adults. Nature. Published online 20 November 2019. Article available on https://doi.org/10.1038/s41586-019-1775-1.

Lauren R. Olafson , Anna H. Siddell, Kathryn M. Field, Madeleine Byrnes, Robert W. Rapkins, Benedict Ng , Sheri Nixdorf, Elizabeth H. Barnes, Terrance G. Johns, Sonia Yip, John Simes, Anna K. Nowak,  Mark A. Rosenthal, Kerrie L. McDonald. Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: A subset analysis of the CABARET trial. Journal of Clinical Neuroscience. Published online 30 Sep 2019. Article available on  https://doi.org/10.1016/j.jocn.2019.08.044.

TRAVELING WITH CANCER: A GUIDE FOR ONCOLOGISTS IN THE MODERN WORLD
Sharon Heng, Brett Hughes, Michael Hibbert, Mustafa Khasraw, Zarnie Lwin. Traveling With Cancer: A Guide for Oncologists in the Modern World. Journal of Global Oncology. Published online 10 July 2019. Article available on https://doi.org/10.1200/JGO.19.00029

 

OUTCOMES AFTER SECOND SURGERY FOR RECURRENT GLIOBLASTOMA: A RETROSPECTIVE CASE-CONTROL STUDY
Alysson Wann, Patrick A. Tully, Elizabeth H. Barnes, Zarnie Lwin, Rosalind Jeffree, Katharine J. Drummond, Hui Gan, Mustafa Khasraw. Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study. Journal of Neuro-Oncology. Published online 2 January 2018. Article available on http://dx.doi.org/10.1007/s11060-017-2731-2

 

COMPARISON BETWEEN SITE AND CENTRAL RADIOLOGICAL ASSESSMENTS FOR PATIENTS WITH RECURRENT GLIOBLASTOMA ON A CLINICAL TRIAL
Kathryn M. Field, Greg Fitt, Mark A. Rosenthal, John Simes, Anna K. Nowak, Elizabeth H. Barnes, Kate Sawkins, Christine Goh, Bradford A. Moffat, Simon Salinas, Lawrence Cher, Helen Wheeler, Elizabeth J. Hovey, Pramit M. Phal, CABARET/COGNO Investigators. Comparison between site and central radiological assessments for patients with recurrent glioblastoma on a clinical trial. Asia-Pacific Journal of Clinical Oncology. Published online 8 November 2017. Article available on http://dx.doi.org/10.1111/ajco.12806

 

INTERIM RESULTS FROM THE CATNON TRIAL (EORTC STUDY 26053-22054) OF TREATMENT WITH CONCURRENT AND ADJUVANT TEMOZOLOMIDE FOR 1P/19Q NON-CO-DELETED ANAPLASTIC GLIOMA: A PHASE 3, RANDOMISED, OPEN-LABEL INTERGROUP STUDY
Martin J van den Bent, Brigitta Baumert, Sara C Erridge, Michael A Vogelbaum, Anna K Nowak, Marc Sanson, Alba Ariela Brandes, Paul M Clement, Jean Francais Baurain, Warren P Mason, Helen Wheeler, Olivier L Chinot, Sanjeev Gill, Matthew Griffin, David G Brachman, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Jaap Reijneveld, Roelien H Enting, Damien C Weber, Thierry Lesimple, Susan Clenton, Anja Gijtenbeek, Sarah Pascoe, Ulrich Herrlinger, Peter Hau, Frederic Dhermain, Irene van Heuvel, Roger Stupp, Ken Aldape, Robert B Jenkins, Hendrikus Jan Dubbink, Winand N M Dinjens, Pieter Wesseling, Sarah Nuyens, Vassilis Golfinopoulos, Thierry Gorlia, Wolfgang Wick, Johan M Kros. Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. The Lancet. Published online 8 August 2017. Article available on http://dx.doi.org/10.1016/S0140-6736(17)31442-3

 

THE ROLE OF EARLY MRI IN PREDICTING SURVIVAL WHILE ON BEVACIZUMAB IN RECURRENT GLIOBLASTOMA: RESULTS FROM A PROSPECTIVE CLINICAL TRIAL (CABARET)
Field KM, Phal PM, Fitt G, Goh C, Nowak AK, Rosenthal MA, Simes J, Barnes EH, Sawkins K, Cher LM, Hovey EJ, Wheeler H. The role of early MRI in predicting survival while on bevacizumab in recurrent glioblastoma: results from a prospective clinical trial (CABARET). Cancer. Published online 5 June 2017. Article available on http://dx.doi.org/10.1002/cncr.30838

HEALTH-RELATED QUALITY OF LIFE OUTCOMES FROM CABARET: A RANDOMIZED PHASE 2 TRIAL OF CARBOPLATIN AND BEVACIZUMAB IN RECURRENT GLIOBLASTOMA
Kathryn M. Field, Madeleine T. King, John Simes, David Espinoza, Elizabeth H. Barnes, Kate Sawkins, Mark A. Rosenthal, Lawrence Cher, Elizabeth Hovey, Helen Wheeler, Anna K. Nowak. Health-related quality of life outcomes from CABARET: a randomized phase 2 trial of carboplatin and bevacizumab in recurrent glioblastoma. Journal of Neuro-Oncology. Published online 22 May 2017. Article available on http://dx.doi.org/10.1007/s11060-017-2479-8

 

VELIPARIB IN COMBINATION WITH RADIOTHERAPY FOR THE TREATMENT OF MGMT UNMETHYLATED GLIOBLASTOMA (PRE-CLINICAL WORK FOR VERTU)
Jue TR, Nozue K, Lester AJ, Joshi S, Schroder LB, Whittaker SP, Nixdorf S, Rapkins RW, Khasraw M, McDonald KL. Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma (pre-clinical work for VERTU). Journal of Translational Medicine. Published online 17 March 2017. Article available on http://dx.doi.org/10.1186/s12967-017-1164-1

 

EARLY PERFUSION MRI PREDICTS SURVIVAL OUTCOME IN PATIENTS WITH RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB AND CARBOPLATIN
Bennett IE, Field KM, Hovens CM, Moffat BA, Rosenthal MA, Drummond K, Kaye AH, Morokoff AP. Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin. Journal of Neuro-Oncology. Published online 28 November 2016. Article available on https://doi.org/10.1007/s11060-016-2300-0

COMBINING PARP INHIBITORS WITH RADIATION THERAPY FOR THE TREATMENT OF GLIOBLASTOMA: IS PTEN PREDICTIVE OF RESPONSE? (PRE-CLINICAL WORK FOR VERTU)
Lester A, Rapkins R, Nixdorf S, Khasraw M, McDonald K. Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response? (pre-clinical work for VERTU). Clinical and Translational Oncology. Published online 21 September 2016. Article available on http://dx.doi.org/10.1007/s12094-016-1547-4

EVOLVING MANAGEMENT OF LOW GRADE GLIOMA: NO CONSENSUS AMONGST TREATING CLINICIANS
KM Field, MA Rosenthal, M Khasraw, K Sawkins, AK Nowak. Evolving Management of Low Grade Glioma: No Consensus Amongst Treating Clinicians. Journal of Clinical Neuroscience. Published online January 2016. Article available on https://doi.org/10.1016/j.jocn.2015.05.038

IMPACT OF COGNITIVE FUNCTION ON COMMUNICATION IN PATIENTS WITH PRIMARY OR SECONDARY BRAIN TUMOURS (COGNO ENDORSED STUDY)

Diana N. Naehrig, Eng-Siew Koh, Monica Vogiatzis, Waka Yanagisawa, Carol Kwong, Heather L. Shepherd, Chris Milross, Haryana M. Dhillon. Impact of cognitive function on communication in patients with primary or secondary brain tumours. Journal of Neuro-Oncology. Published online 26 October 2015. Article available on http://link.springer.com/article/10.1007%2Fs11060-015-1964-1

VALIDATING SELF-REPORT AND PROXY REPORTS OF THE DEXAMETHASONE SYMPTOM QUESTIONNAIRE -CHRONIC FOR THE EVALUATION OF LONGER-TERM CORTICOSTEROID TOXICITY
Meera Agar, Eng-Siew Koh, Emma Gibbs, Elizabeth H. Barnes, Elizabeth Hovey, Ann Livingstone, Kate Sawkins, Richard Chye, Melanie R. Lovell, Katherine Clark, Janette Vardy, Madeleine King, On behalf of the Cooperative Trials Group for Neuro-Oncology (COGNO). Validating self-report and proxy reports of the Dexamethasone Symptom Questionnaire -Chronic for the evaluation of longer-term corticosteroid toxicity. Supportive Care in Cancer. Published online 21 August 2015. Article available on http://link.springer.com/article/10.1007/s00520-015-2897-0

RANDOMIZED PHASE 2 STUDY OF CARBOPLATIN AND BEVACIZUMAB IN RECURRENT GLIOBLASTOMA
Kathryn M. Field, John Simes, Anna K. Nowak, Lawrence Cher, Helen Wheeler, Elizabeth J. Hovey, Christopher S.B. Brown, Elizabeth H. Barnes, Kate Sawkins, Ann Livingstone, Ron Freilich, Pramit M. Phal, Greg Fitt, CABARET/COGNO investigators and Mark A. Rosenthal. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma. Neuro-Oncology. Published online 30 June 2015. Article available on https://doi.org/10.1093/neuonc/nov104

PATTERNS OF CARE IN ADULT MEDULLOBLASTOMA
Cosman R, Brown CSB, DeBraganca KC, Khasraw M, for the Cooperative Trials Group for Neuro-Oncology (COGNO). Patterns of care in adult medulloblastoma: results of an international online survey. Journal of Neuro-Oncology. 16 July 2014 Epub ahead of print. Article available on http://link.springer.com/article/10.1007/s11060-014-1525-z

CULTURALLY AND LINGUISTICALLY DIVERSE PATIENT PARTICIPATION IN GLIOMA RESEARCH
Lwin Z, Broom A, Cosman R, Livingstone A, Sawkins K, Good P, Kirby E, Koh ES and Hovey E on behalf of the COGNO CALD working group. Culturally and linguistically diverse patient participation in glioma research. Neuro-Oncology Practice. 25 June 2014 Epub ahead of print. Article available on http://dx.doi.org/10.1093/nop/npu009

NEURO-ONCOLOGY PRACTICES IN AUSTRALIA
Chen JY, Hovey E, Rosenthal M, Livingstone A, Simes J, for the Cooperative Trials Group for Neuro-Oncology (COGNO). Neuro-Oncology practices in Australia: A Cooperative Group for Neuro-Oncology patterns of care study. Asia-pacific Journal of Clinical Oncology. 29 May 2013 Epub ahead of print. Article available on http://dx.doi.org/10.1111/ajco.12079

GLIOBLASTOMA MULTIFORME
Ananda S, Nowak AK, Cher L, Dowling A, Brown C, Simes J, Rosenthal MA, for the Cooperative Trials Group for Neuro-Oncology (COGNO). Phase 2 trial of temozolomide and pegylated liposomal doxorubicin in the treatment of patients with glioblastoma multiforme following concurrent radiotherapy and chemotherapy. Journal of Clinical Neuroscience. Published online 2 August 2011. Article available on https://linkinghub.elsevier.com/retrieve/pii/S0967-5868(11)00222-0